- Home
- EQBK vs ARVN Comparison
EQBK vs ARVN Comparison
Compare EQBK & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQBK
- ARVN
- Stock Information
- Founded
- EQBK 2002
- ARVN 2015
- Country
- EQBK United States
- ARVN United States
- Employees
- EQBK N/A
- ARVN N/A
- Industry
- EQBK Major Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- EQBK Finance
- ARVN Health Care
- Exchange
- EQBK Nasdaq
- ARVN Nasdaq
- Market Cap
- EQBK 673.9M
- ARVN 614.8M
- IPO Year
- EQBK 2015
- ARVN 2018
- Fundamental
- Price
- EQBK $40.78
- ARVN $6.07
- Analyst Decision
- EQBK Hold
- ARVN Buy
- Analyst Count
- EQBK 6
- ARVN 19
- Target Price
- EQBK $44.20
- ARVN $21.14
- AVG Volume (30 Days)
- EQBK 53.1K
- ARVN 3.3M
- Earning Date
- EQBK 04-15-2025
- ARVN 05-01-2025
- Dividend Yield
- EQBK 1.47%
- ARVN N/A
- EPS Growth
- EQBK 543.36
- ARVN N/A
- EPS
- EQBK 3.93
- ARVN N/A
- Revenue
- EQBK $224,743,000.00
- ARVN $426,900,000.00
- Revenue This Year
- EQBK $20.11
- ARVN N/A
- Revenue Next Year
- EQBK $10.81
- ARVN N/A
- P/E Ratio
- EQBK $10.39
- ARVN N/A
- Revenue Growth
- EQBK 56.29
- ARVN 498.74
- 52 Week Low
- EQBK $31.75
- ARVN $5.94
- 52 Week High
- EQBK $50.85
- ARVN $37.38
- Technical
- Relative Strength Index (RSI)
- EQBK 63.71
- ARVN 31.46
- Support Level
- EQBK $38.81
- ARVN $6.51
- Resistance Level
- EQBK $41.64
- ARVN $7.05
- Average True Range (ATR)
- EQBK 0.76
- ARVN 0.58
- MACD
- EQBK 0.33
- ARVN -0.13
- Stochastic Oscillator
- EQBK 78.66
- ARVN 1.37
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.